U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10NO6P.H2O
Molecular Weight 265.1571
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PYRIDOXAL PHOSPHATE

SMILES

O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O

InChI

InChIKey=CEEQUQSGVRRXQI-UHFFFAOYSA-N
InChI=1S/C8H10NO6P.H2O/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14;/h2-3,11H,4H2,1H3,(H2,12,13,14);1H2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20532028 | https://clinicaltrials.gov/ct2/show/NCT00157729 | https://clinicaltrials.gov/ct2/show/NCT00917293 | https://www.ncbi.nlm.nih.gov/pubmed/12213051 | https://www.ncbi.nlm.nih.gov/pubmed/23510563

Pyridoxal phosphate (PLP, pyridoxal 5'-phosphate, P5P) is a coenzyme, the active form of vitamin B6. Pyridoxal 5′-phosphate (PLP) is used as a cofactor for a wide range of enzymes including mitochondrial cysteine desulfurase, cystathionine γ-synthase (CGS), ornithine 4,5-aminomutase (OAM), and d-serine dehydratase. The versatility of PLP arises from its ability to covalently bind the substrate, and then to act as an electrophilic catalyst, thereby stabilizing different types of carbanionic reaction intermediates. PLP acts as a coenzyme in all transamination reactions, in various beta-elimination reactions, in the condensation reaction in heme synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3000.0 nM [EC50]
39500.0 nM [EC50]
10.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
220.7 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered: FURSULTIAMINE
PYRIDOXAL PHOSPHATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
653.7 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered: FURSULTIAMINE
PYRIDOXAL PHOSPHATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.2 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered: FURSULTIAMINE
PYRIDOXAL PHOSPHATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
750 mg 1 times / day multiple, oral
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Cloning, sequencing, heterologous expression, purification, and characterization of adenosylcobalamin-dependent D-ornithine aminomutase from Clostridium sticklandii.
2001-11-30
ABA3 is a molybdenum cofactor sulfurase required for activation of aldehyde oxidase and xanthine dehydrogenase in Arabidopsis thaliana.
2001-11-02
Crystal structures of 1-aminocyclopropane-1-carboxylate (ACC) synthase in complex with aminoethoxyvinylglycine and pyridoxal-5'-phosphate provide new insight into catalytic mechanisms.
2001-10-12
COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk.
2001-10
Plants synthesize ethanolamine by direct decarboxylation of serine using a pyridoxal phosphate enzyme.
2001-09-21
Smooth muscle does not have a common P2x receptor phenotype: expression, ontogeny and function of P2x1 receptors in mouse ileum, bladder and reproductive systems.
2001-09-17
Properties and interaction of heterologously expressed glutamate decarboxylase isoenzymes GAD(65kDa) and GAD(67kDa) from human brain with ginkgotoxin and its 5'-phosphate.
2001-09-13
ATP P2X receptor-mediated enhancement of glutamate release and evoked EPSCs in dorsal horn neurons of the rat spinal cord.
2001-09-01
P2Y(AC)(-)-receptor agonists enhance the proliferation of rat C6 glioma cells through activation of the p42/44 mitogen-activated protein kinase.
2001-09
Cloning and characterization of a functional P2X receptor from larval bullfrog skin.
2001-09
Crystal structure of histidinol phosphate aminotransferase (HisC) from Escherichia coli, and its covalent complex with pyridoxal-5'-phosphate and l-histidinol phosphate.
2001-08-24
Structure of human cystathionine beta-synthase: a unique pyridoxal 5'-phosphate-dependent heme protein.
2001-08-01
P2X3 knock-out mice reveal a major sensory role for urothelially released ATP.
2001-08-01
Crystal structure of maltose phosphorylase from Lactobacillus brevis: unexpected evolutionary relationship with glucoamylases.
2001-08
Production of pyridoxal phosphate by a mutant strain of Schizosaccharomyces pombe.
2001-08
Clinical and cost effectiveness of a new hepatocellular MRI contrast agent, mangafodipir trisodium, in the preoperative assessment of liver resectability.
2001-08
A bioinformatical approach suggests the function of the autoimmune hepatitis target antigen soluble liver antigen/liver pancreas.
2001-08
X-ray structure of Escherichia coli pyridoxine 5'-phosphate oxidase complexed with pyridoxal 5'-phosphate at 2.0 A resolution.
2001-07-20
The human cDNA for a homologue of the plant enzyme 1-aminocyclopropane-1-carboxylate synthase encodes a protein lacking that activity.
2001-07-11
Influence of pyridoxal 5'-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy.
2001-07-01
Serum cystatin C is an independent predictor of total homocysteine levels in stable Korean renal transplant recipients with normal serum creatinine.
2001-07
Nucleotide-evoked relaxation of rat vas deferens--a possible role for endogenous ATP released upon alpha(1)-adrenoceptor stimulation.
2001-06-22
Role of endogenous ATP at the incision area in a rat model of postoperative pain.
2001-06-13
Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels.
2001-06-12
Effect of vitamin B6 deficiency on the synthesis and accumulation of S-adenosylhomocysteine and S-adenosylmethionine in rat tissues.
2001-06
Effect of feeding on circulating micronutrient concentrations in the Burmese python (Python molurus).
2001-06
Stimulation of P2 receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo.
2001-06
Cassette mutagenesis of lysine 130 of human glutamate dehydrogenase. An essential residue in catalysis.
2001-06
Sensitivity to meat protein intake and hyperoxaluria in idiopathic calcium stone formers.
2001-06
PPADS, an ATP antagonist, attenuates the effects of a moderately intense sound on cochlear mechanics.
2001-06
Dephosphorylation of MnDPDP and related compounds by acid and alkaline phosphatase.
2001-06
ATP affects both axons and Schwann cells of unmyelinated C fibres.
2001-06
Accelerated functional recovery after neuronal injury by P2 receptor blockade.
2001-05-25
Molecular cloning and functional expression of Xenopus laevis oocyte ATP-activated P2X4 channels.
2001-05-02
Three-dimensional structure of 2-amino-3-ketobutyrate CoA ligase from Escherichia coli complexed with a PLP-substrate intermediate: inferred reaction mechanism.
2001-05-01
Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells.
2001-05
Lack of catalytic activity of a murine mRNA cytoplasmic serine hydroxymethyltransferase splice variant: evidence against alternative splicing as a regulatory mechanism.
2001-04-24
The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: possible involvement of vanilloid receptors.
2001-04
Renal microvascular effects of P2 receptor stimulation.
2001-04
Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate.
2001-03
Crystal structure of threonine synthase from Arabidopsis thaliana.
2001-03
Adult hypophosphatasia. Current aspects.
2001-03
A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting.
2001-03
Effect of phosphate on stability of pyridoxal in the presence of lysine.
2001-03
Inhibitors of advanced glycation end product-associated protein cross-linking.
2001-02-14
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
2001-02-01
Inhibitory effect of glycation on catalytic activity of alanine aminotransferase.
2001-02
Metal ion inhibition of nonenzymatic pyridoxal phosphate catalyzed decarboxylation and transamination.
2001-01-17
Correlation of MRI and CT findings with histopathology in hepatic angiomyolipoma.
2001
Testing the tyrosine/catecholamine hypothesis of oral contraceptive-induced psychological side-effects: a controlled study on triphasil.
2001
Patents

Sample Use Guides

500 mgs po bid for 12 weeks.
Route of Administration: Oral
Male Wistar rat (body weight -200 g) was sacrificed by bleeding from the right femoral artery under diethyl ether anesthesia. A thoracic aorta was removed and washed with RPMI 1640 medium to avoid contamination with blood. It was then turned inside out, and cut into short segments of about 1-1.5 mm. Each aortic segment was placed in the center of a well on a 6-well culture plate and covered with 0.5 ml of gel matrix solution reconstituted as described. The solution was allowed to gel at 37°C for 20 min, and then overlaid with 2 ml of RPMI 1640 medium (Gibco, New York, USA) containing 1% of ITS+ (Becton Dickinson Labware, MA, USA). PLP (Pyridoxal phosphate ) was reconstituted in phosphate buffered saline and added on day 1. Incubation was carried out for 10 days in a fully humidified system of 5% C02 in the air at 37°C. The medium was changed on day 7 of the culture.
Name Type Language
PYRIDOXAL PHOSPHATE
MART.  
Common Name English
PYRIDOXAL 5-PHOSPHATE MONOHYDRATE
WHO-DD  
Preferred Name English
PYRIDOXAL PHOSPHATE [MART.]
Common Name English
PYRIDOXAL PHOSPHATE HYDRATE
JAN  
Common Name English
Pyridoxal 5-phosphate monohydrate [WHO-DD]
Common Name English
PYRIDOXAL PHOSPHATE MONOHYDRATE
Common Name English
3-HYDROXY-2-METHYL-5-((PHOSPHONOXY)METHYL)-4-PYRIDINECARBOXALDEHYDE HYDRATE
Common Name English
PYRIDOXAL 5'-PHOSPHATE MONOHYDRATE
Common Name English
PYRIDOXAL PHOSPHATE HYDRATE [JAN]
Common Name English
4-PYRIDINECARBOXALDEHYDE, 3-HYDROXY-2-METHYL-5-((PHOSPHONOOXY)METHYL)-, HYDRATE (1:1)
Systematic Name English
Classification Tree Code System Code
LOINC 75056-2
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
WHO-ATC A11HA06
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
WHO-VATC QA11HA06
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
LOINC 62236-5
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
LOINC 74442-5
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
NCI_THESAURUS C45812
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
LOINC 30552-4
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
FDA ORPHAN DRUG 557116
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
Code System Code Type Description
EVMPD
SUB33483
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
ALTERNATIVE
PUBCHEM
38882
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
EVMPD
SUB04137MIG
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
EPA CompTox
DTXSID7046594
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
SMS_ID
100000127438
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
ChEMBL
CHEMBL82202
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
NCI_THESAURUS
C81627
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
EVMPD
SUB33484
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
DRUG CENTRAL
3506
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
CHEBI
18405
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
DRUG BANK
DB00114
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
RXCUI
9004
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
PYRIDOXAL PHOSPHATE
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
FDA UNII
5V5IOJ8338
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
DAILYMED
5V5IOJ8338
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
CAS
41468-25-1
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY
MESH
D011732
Created by admin on Mon Mar 31 18:24:36 GMT 2025 , Edited by admin on Mon Mar 31 18:24:36 GMT 2025
PRIMARY